{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:03:42Z","timestamp":1772903022461,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Although glecaprevir\/pibrentasvir (GP) therapy is recommended as a first-line treatment for hepatitis C virus (HCV) infection, serious drug-induced liver injury occasionally develops. The present study aimed to elucidate real-world risk factors for GP-induced liver injury and to evaluate the efficacy of add-on ursodeoxycholic acid (UDCA) for liver injury. We analyzed 236 HCV patients who received GP therapy. GP-induced liver injury was defined as any elevation to grade \u2265 1 in total bilirubin (TB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or \u03b3-glutamyl transferase (\u03b3-GT) during treatment without other cause. The frequency of GP-induced liver injury was 61.9% (146\/236). Serious elevation to grade \u2265 3 in TB, AST, ALT, ALP, and \u03b3-GT was identified in 3.8% (9\/236), 0%, 0%, 0%, and 0.4% (1\/209), respectively. Therapy discontinuation and dose reduction were seen in one patient each. Multivariate analysis revealed age and TB as independent risk factors for GP-induced liver injury. In patients with grade \u2265 2 hyperbilirubinemia, TB after onset significantly decreased in the add-on UDCA group but not in the no UDCA group. Careful attention to GP-induced liver injury is warranted for elderly patients with cirrhosis. Add-on UDCA could suppress the aggravation of GP-induced liver injury.<\/jats:p>","DOI":"10.3390\/v15020489","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T03:52:49Z","timestamp":1676001169000},"page":"489","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk Factors of Glecaprevir\/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-4573","authenticated-orcid":false,"given":"Hideyuki","family":"Tamai","sequence":"first","affiliation":[{"name":"Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis","volume":"53","author":"Chayama","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatol. (Baltim. Md.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatol. (Baltim. Md.)"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology (2020). Japan society of hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 50, 791\u2013816.","DOI":"10.1111\/hepr.13503"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series (\u2606)","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e17343","DOI":"10.1097\/MD.0000000000017343","article-title":"A case report of glecaprevir\/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis","volume":"98","author":"Yoon","year":"2019","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e226622","DOI":"10.1136\/bcr-2018-226622","article-title":"Glecaprevir\/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection","volume":"12","author":"Hammami","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.2169\/internalmedicine.6664-20","article-title":"Severe liver injury associated with glecaprevir plus pibrentasvir therapy in a patient with treatment-na\u00efve hepatitis C virus infection","volume":"60","author":"Hara","year":"2021","journal-title":"Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0042-1750716","article-title":"Acute liver injury due to glecaprevir\/pibrentasvir in a patient with chronic hepatitis C virus infection without cirrhosis","volume":"12","author":"Jain","year":"2022","journal-title":"Avicenna J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: An update","volume":"94","author":"Stephens","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"744488","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review","volume":"12","author":"Nezic","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5009\/gnl17048","article-title":"The real-world safety and efficacy of daclatasvir and asunaprevir for elderly patients","volume":"12","author":"Taki","year":"2018","journal-title":"Gut Liver"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","article-title":"Drug-induced liver injury","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00535-019-01569-7","article-title":"Integrated analysis of 8-week glecaprevir\/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection","volume":"54","author":"Naganuma","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: Two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5009\/gnl20321","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II\/III Trials","volume":"15","author":"Heo","year":"2021","journal-title":"Gut Liver"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ijantimicag.2019.07.005","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis","volume":"54","author":"Wang","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","first-page":"125","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection","volume":"9","author":"Liu","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/07853890.2021.2012589","article-title":"Drug-induced liver injury by glecaprevir\/pibrentasvir treatment for chronic hepatitis C infection: A systematic review and meta-analysis","volume":"54","author":"Hung","year":"2022","journal-title":"Ann. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/hepr.13410","article-title":"Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world","volume":"49","author":"Tamori","year":"2019","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hepr.13328","article-title":"Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study","volume":"49","author":"Ogawa","year":"2019","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2185\/jrm.2020-004","article-title":"Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection","volume":"15","author":"Watanabe","year":"2020","journal-title":"J. Rural. Med. JRM"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12072-020-10019-z","article-title":"The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: A comprehensive analysis of a prospective multicenter study","volume":"14","author":"Nozaki","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Komaki, Y., Ozono, Y., Nakamura, K., Iwakiri, H., Hasuike, S., Sueta, M., Miike, T., Yamamoto, S., Uto, H., and Kusumoto, K. (2022). Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02284-z"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1002\/hsr2.458","article-title":"Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1\/2 hepatitis C virus infection","volume":"5","author":"Miyasaka","year":"2022","journal-title":"Health Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00228-018-2576-4","article-title":"Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment","volume":"75","author":"Kosloski","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(99)80223-2","article-title":"Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury","volume":"31","author":"Tanaka","year":"1999","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/489\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:29:25Z","timestamp":1760120965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020489"],"URL":"https:\/\/doi.org\/10.3390\/v15020489","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}